 This study found that Resanchezumab did not meet the primary endpoint of achieving higher rates of high SCR compared to placebo. However, the study did show that Resanchezumab had a similar rate of high SCR as placebo when administered at doses of 180 mg and 360 mg. Additionally, the incidence of TEAEs was generally low and comparable across treatment groups. This article was authored by Alexa B. Kimball, Errol P. Prens, Thierry Pasirin, and others.